Atlas Trials

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Clinical trial NCT04965519 · UNKNOWN

Trial details

NCT number
NCT04965519
Sponsor
RemeGen Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gynecological Malignancy
Start date
2021-12-21
Primary completion
2024-10-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.